Send to

Choose Destination
See comment in PubMed Commons below
Am J Med Sci. 2004 Apr;327(4):212-6.

An analog peptide that suppresses collagen-induced arthritis.

Author information

Department of Pediatrics and Medicine, University of Tennessee, and from the Research Service of the Veterans Affairs Medical Center, Memphis, Tennessee, USA.


The authors undertook the identification of peptides capable of altering the immune response to type II collagen (CII) in the context of HLA-DR, as suppressing the immune response to CII could clarify the role of CII autoimmunity in the pathogenesis of disease. To produce synthetic peptides with the potential of disrupting the DR1-restricted immune response, synthetic analog peptides were developed that contain site-directed substitutions in critical positions. When these analog peptides were used to treat collagen-induced arthritis in DR1 transgenic mice, an analog peptide, CII 256-276 (N, D), was identified that inhibited T-cell responses in vitro. The data from studies with this analog peptide establish that CII 256-276 (N, D) is a potent suppressor of the DR-mediated immune response to CII and that its effect is mediated, at least in part, by interleukin-4. An analog peptide of CII recognized by T cells in the context of a human major histocompatibility complex molecule should have therapeutic significance for autoimmune arthritis.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center